These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 12186361

  • 1. Type I Gaucher disease in children with and without enzyme therapy.
    Dweck A, Abrahamov A, Hadas-Halpern I, Bdolach-Avram T, Zimran A, Elstein D.
    Pediatr Hematol Oncol; 2002 Sep; 19(6):389-97. PubMed ID: 12186361
    [Abstract] [Full Text] [Related]

  • 2. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 3. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
    Andersson H, Kaplan P, Kacena K, Yee J.
    Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
    [Abstract] [Full Text] [Related]

  • 4. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 5. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India.
    Nagral A, Mewawalla P, Jagadeesh S, Kabra M, Phadke SR, Verma IC, Puri RD, Gupta N, Kishnani PS, Mistry PK.
    Indian Pediatr; 2011 Oct; 48(10):779-84. PubMed ID: 22080680
    [Abstract] [Full Text] [Related]

  • 6. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
    Kauli R, Zaizov R, Lazar L, Pertzelan A, Laron Z, Galatzer A, Phillip M, Yaniv Y, Cohen IJ.
    Isr Med Assoc J; 2000 Feb; 2(2):158-63. PubMed ID: 10804944
    [Abstract] [Full Text] [Related]

  • 7. Enzyme replacement therapy for Gaucher disease in Australia.
    Goldblatt J, Szer J, Fletcher JM, McGill J, Rowell JA, Wilson M.
    Intern Med J; 2005 Mar; 35(3):156-61. PubMed ID: 15737135
    [Abstract] [Full Text] [Related]

  • 8. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G, Ponce E, Basack N, Freigeiro D, Aversa L, Graciela E, Kohan R.
    J Pediatr; 2007 Aug; 151(2):197-201. PubMed ID: 17643778
    [Abstract] [Full Text] [Related]

  • 9. [Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease].
    Pérez-Calvo JI, Giraldo P, Giralt M.
    Sangre (Barc); 1997 Jun; 42(3):189-94. PubMed ID: 9381260
    [Abstract] [Full Text] [Related]

  • 10. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.
    Grigorescu Sido P, Drugan C, Cret V, Al-Kzouz C, Denes C, Coldea C, Zimmermann A.
    J Inherit Metab Dis; 2007 Oct; 30(5):783-9. PubMed ID: 17703370
    [Abstract] [Full Text] [Related]

  • 11. Enzyme replacement therapy in type I Gaucher disease.
    Kay AC, Saven A, Garver P, Thurston DW, Rosenbloom BF, Beutler E.
    Trans Assoc Am Physicians; 1991 Oct; 104():258-64. PubMed ID: 1845151
    [No Abstract] [Full Text] [Related]

  • 12. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
    Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A.
    Am J Med; 2002 Aug 01; 113(2):112-9. PubMed ID: 12133749
    [Abstract] [Full Text] [Related]

  • 13. Enzyme replacement therapy in a child with Gaucher disease.
    Masood Y, Ali AS.
    J Coll Physicians Surg Pak; 2006 Dec 01; 16(12):786-8. PubMed ID: 17125641
    [Abstract] [Full Text] [Related]

  • 14. [Enzyme replacement therapy for Gaucher paediatric disease: the only Tunisian experience].
    Ben Turkia H, Azzouz H, Tebib N, Abdelmoula MS, Ben Chehida A, Hlel Y, Caillaud C, Sahli H, Ben Dridi MF.
    Tunis Med; 2009 May 01; 87(5):344-8. PubMed ID: 19927767
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.
    Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Elstein D, Paz A, Brill-Almon E, Chertkoff R.
    Blood Cells Mol Dis; 2015 Jan 01; 54(1):9-16. PubMed ID: 25453586
    [Abstract] [Full Text] [Related]

  • 16. Hematologic response in type I Gaucher's disease after enzyme replacement therapy.
    Parco S, Bruno G, Durighello M, Giorgini R, Simeone R, Bembi B.
    Haematologica; 1999 Apr 01; 84(4):376-7. PubMed ID: 10190956
    [No Abstract] [Full Text] [Related]

  • 17. A phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of Abcertin® in patients with type 1 Gaucher disease.
    Choi JH, Lee BH, Ko JM, Sohn YB, Lee JS, Kim GH, Heo SH, Park JY, Kim YM, Kim JH, Yoo HW.
    J Korean Med Sci; 2015 Apr 01; 30(4):378-84. PubMed ID: 25829804
    [Abstract] [Full Text] [Related]

  • 18. Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply.
    Zimran A, Altarescu G, Elstein D.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):111-4. PubMed ID: 20542712
    [Abstract] [Full Text] [Related]

  • 19. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
    Hollak CE, Belmatoug N, Cole JA, Vom Dahl S, Deegan PB, Goldblatt J, Rosenbloom B, van Dussen L, Tylki-Szymańska A, Weinreb NJ, Zimran A, Cappellini MD.
    Br J Haematol; 2012 Aug 15; 158(4):528-38. PubMed ID: 22640238
    [Abstract] [Full Text] [Related]

  • 20. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
    Piran S, Roberts A, Patterson MA, Amato D.
    Blood Cells Mol Dis; 2009 Aug 15; 43(3):289-93. PubMed ID: 19793665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.